Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978320 | 1.00 | KMT2A (0.39) | KMT2AMETAP2HSD11B1MAPTMAPK1 | |
| SCHEMBL4748532 | 0.70 | HSD11B1 (0.39) | KMT2AMETAP2HSD11B1MAPK1OPRL1 | |
| SCHEMBL740951 | 0.69 | KMT2A (0.44) | KMT2AMETAP2HSD11B1MAPTMAPK1 | |
| SCHEMBL3977640 | 0.69 | KMT2A (0.44) | KMT2AMETAP2HSD11B1MAPTMAPK1 | |
| SCHEMBL3976212 | 0.68 | KMT2A (0.43) | KMT2AMETAP2HSD11B1MAPTMAPK1 | |
| SCHEMBL4169655 | 0.68 | KMT2A (0.46) | KMT2AMETAP2HSD11B1MAPTMAPK1 | |
| SCHEMBL3978062 | 0.68 | KMT2A (0.46) | KMT2AMETAP2HSD11B1MAPTMAPK1 | |
| SCHEMBL3981420 | 0.68 | KMT2A (0.46) | KMT2AMETAP2HSD11B1MAPTMAPK1 | |
| SCHEMBL12167676 | 0.68 | KMT2A (0.42) | KMT2AMETAP2HSD11B1MAPK1ALDH1A1 | |
| SCHEMBL12167710 | 0.68 | KMT2A (0.42) | KMT2AMETAP2HSD11B1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563805-B2 | 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | QTRT1, RRS1, LAS1L | KMT2A 2638/4885METAP2 4222/4885HSD11B1 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.